Samsung Bioepis' Opuviz (Aflibercept) Biosimilar Receives European Approval for Ophthalmic Use

Samsung Bioepis (搜索)搜索该词条 has secured European approval for Opuviz查看药品详情, its biosimilar of aflibercept查看药品详情, marking its second foray into treatments for eye diseases. This approval follows a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in September.

The approval allows Samsung Bioepis (搜索)搜索该词条 to broaden its ophthalmic treatment offerings, building on its existing product, Byooviz (ranibizumab). Opuviz查看药品详情 is a biosimilar to Eylea查看药品详情, a drug developed by Regeneron Pharmaceuticals查看公司主页 that addresses conditions such as neovascular age-related macular degeneration (搜索)搜索该疾病 (AMD). Eylea functions by binding to vascular endothelial growth factor (VEGF (搜索)搜索该靶点), thereby inhibiting the formation of abnormal blood vessels.

Mechanism of Action and Clinical Significance

Aflibercept查看药品详情, the active ingredient in both Eylea查看药品详情 and Opuviz查看药品详情, is a recombinant fusion protein that acts as a VEGF (搜索)搜索该靶点 inhibitor. VEGF is a key mediator in angiogenesis, the formation of new blood vessels, which plays a critical role in the pathology of neovascular AMD. By inhibiting VEGF, aflibercept can reduce the growth of these abnormal blood vessels, slowing the progression of the disease and preserving vision.

Age-related macular degeneration (搜索)搜索该疾病 involves the deterioration of the macula, the central part of the retina, due to aging or inflammation, leading to impaired vision and potential blindness. Neovascular AMD, also known as wet AMD, is characterized by the growth of abnormal blood vessels under the retina, which can leak fluid and blood, causing rapid vision loss. Eylea查看药品详情, and now Opuviz查看药品详情, offers a therapeutic option by targeting the underlying cause of this abnormal blood vessel growth.

Market Impact and Company Strategy

Eylea查看药品详情 generates approximately 12 trillion won ($8.6 billion) in annual global sales, underscoring the significant market for AMD treatments. The introduction of Opuviz查看药品详情 as a biosimilar aims to provide a more cost-effective alternative, potentially increasing access to treatment for patients with neovascular AMD.

"We are pleased to offer patients expanded treatment options," stated Jung Byoung-in, director of regulatory affairs at Samsung Bioepis (搜索)搜索该词条. "We will continue our efforts to provide a diverse range of biopharmaceuticals."

This approval represents Samsung Bioepis (搜索)搜索该词条’ ninth product approval in Europe, further solidifying its position in the biopharmaceutical market.